FDA
-
-
-
-
-
-
-
BeOne Medicines reports positive phase 3 cancer trial results
-
-
-
-
-
-
-
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
-
-
-
-
-
-
-
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
-
-
-
-
-
-
-
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
-
-
-
-
-
-
-
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
-
-
-
-
-
-
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
-
-
-
-
-
-
-
BeiGene (BGNE) Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic ESCC After Prior Chemotherapy
-
329,420 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

